PMVP 8-K SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

PMVP ▼ -11.97% at T+5d

NEUTRAL call ✗ call lost -11.97% · α vs SPY -12.05% · entry $1.42 → $1.25

Next anchor: T+20d in 10h

Currently $1.05 · -26.06% from $1.42 entry

Entry anchored
May 11, 03:59 PM ET
via Databento tick

T+1d

-9.15%

call -9.15% · α -9.73%

$1.29

settled 28d ago

T+5d

-11.97%

call -11.97% · α -12.05%

$1.25

settled 22d ago

T+20d

—

call — · α —

—

in 10h

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

PMV Pharma reported Q1 2026 net loss per share of -$0.34, in line with the year-ago period and beating consensus estimates of -$0.39, though the company remains pre-revenue. Clinical progress continued with rezatapopt NDA submission on track for Q1 2027 and cash runway to end of Q2 2027. The filing is routine with no material change in financial trajectory.

Actionable Insight

Monitor for the NDA submission in Q1 2027 and potential partnership or licensing deals that could extend cash runway. The stock is likely to trade on clinical catalysts rather than quarterly financial results.

Key Facts

Net loss per share of -$0.34 (unchanged YoY) on net loss of $18.0M
Cash, cash equivalents, and marketable securities of $93.5M as of March 31, 2026
Net cash used in operations was $19.7M in Q1 2026 vs $18.3M in Q1 2025
NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer on track for Q1 2027
Orphan Drug Designation granted by FDA for rezatapopt in TP53 Y220C positive ovarian cancer

Financial Impact

No revenue; net loss $18.0M vs $17.4M YoY; cash burn increase of ~$1.4M

net losscash burn

Risk Factors

Clinical trial failure or regulatory delay for rezatapopt
Cash runway only to end of Q2 2027, requiring financing before NDA approval
No approved products and no revenue

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

91% bullish (11 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-218225
Document: pmvp-20260512.htm	0001193125-26-218225
Document: 0001193125-26-218225-index-headers.html	0001193125-26-218225
Document: 0001193125-26-218225-index.html	0001193125-26-218225
Document: 0001193125-26-218225.txt	0001193125-26-218225
8-K Data (Synthetic)	0001193125-26-218225

4 reports for PMVP

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PMVP — sortable, filterable
	Type				Now
May 12, 2026 28d ago	8-K NEUTRAL ★ 3/10	$1.42 $1.25	▼ −11.97%	▼ −12.05%	$1.05 (−26.06%)
May 12, 2026 28d ago	Press Release BULLISH ★ 5/10	$1.42 $1.25	▼ −11.97%	▼ −12.05%	$1.05 (−26.06%)
Apr 22, 2026 6w ago	DEFA14A NEUTRAL ★ 3/10	$1.48 $1.41	▼ −5.07%	▼ −5.12%	$1.05 (−29.05%)
Mar 6, 2026 13w ago	Press Release MIXED ★ 6/10	$1.64 $1.56	▼ −4.88%	▼ −3.35%	$1.05 (−35.98%)

US Market Status

Market Closed — Opens Thu (11h 17m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access